Optibrium and AstraZeneca sign agreement for global license of StarDrop

Optibrium, a developer of software for drug discovery, today announced that AstraZeneca has signed an agreement to license Optibrium’s StarDrop software.


 
Optibrium Ltd.
 
Optibrium, a developer of software for drug discovery, todayannounced that AstraZeneca has signed an agreement to license Optibrium'sStarDrop software.  The agreement willsee the global deployment of StarDrop and the ADME-QSAR and Auto-Modellermodules to AstraZeneca's researchers. StarDrop is a software suite that helpsto deliver optimally balanced, effective drugs. By quickly highlightingdiverse, high-quality compounds, StarDrop dramatically reduces the time ittakes to find effective leads and then transform them into candidate drugs,which will have a high probability of success downstream.
 
Optibrium Ltd.
 


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue